Drug-resistant infections are an increasing threat to global health. Drug (antimicrobial) resistant infections currently claim at least 50,000 lives each year across Europe and the US alone. It is estimated that if action is not taken to address this threat, drug-resistant infections will cause an additional ten million deaths by the year 2050.
The National Institute for Health Research (NIHR) has funded the development of a number of Health Protection Research Units (HPRU) in key priority areas. These research units are collaborations between Universities, Public Health England (PHE) and other partner organisations and aim to provide centres of excellence in multi-disciplinary health protection research.
The NIHR HPRU in Healthcare Associated Infections (HCAI) and Antimicrobial Resistance (AMR) at Imperial College London, started on 1 April 2014. It was funded as a result of a new initiative to bring Universities into partnership with Public Health England to carry out research across 12 public health priority areas, ranging from immunisation to radiation hazards. The HPRU in HCAI and AMR has as its partners:
- Public Health England
- Wellcome Trust Sanger Institute
- Cambridge Veterinary School
- North West London Academic Health Science Network (Imperial College Health Partners)
The Unit is directed by a Strategy Management and Operations Committee which consists of the Director, PHE lead and theme leads - this is in turn advised by a Scientific Advisory Board.